Lipid-bound factor Xa regulates tissue factor activity.
The activation of coagulation factor X by tissue factor (TF) and coagulation factor VIIa (VIIa) on a phospholipid surface is thought to be the key step in the initiation of blood coagulation. In this reaction, the product, fXa, is transiently and reversibly bound to the TF-VIIa enzyme complex. This in effect leads to a probabilistic inhibition of subsequent fX activations; a new fX substrate molecule cannot be activated until the old fXa molecule leaves. In this study, we demonstrate that benzamidine and soybean trypsin inhibitor-conjugated Sepharose beads, which bind fXa and sequester it away from the reaction, serve to enhance fX activation by the TF-VIIa complex. Thus, removal of fXa from the reactive zone, by either flow, fXa sequestration, or binding to distant lipid surfaces, can serve to enhance the levels of TF-VIIa activity. Using resonance energy transfer, we found the dissociation constants of fX and fXa for 100 nm diameter phospholipid vesicles to be on the order of 30-60 nM, consistent with previous measurements employing planar lipid surfaces. On the basis of the measurements of binding of fXa to phospholipid surfaces, we demonstrate that the rates of fX activation by the TF-VIIa complex under a variety of experimental conditions depend inversely on the amount of product (fXa) bound to the TF-phospholipid surface. These data support an inhibitory role for the reaction product, fXa, and indicate that models previously employed in understanding this initial coagulation reaction must now be re-evaluated to account for both the product occupancy of the phospholipid surface and the binding of the product to the enzyme. Moreover, the inhibitory properties of fXa can be described on the basis of the estimated surface density of fXa molecules on the TF-phospholipid surface.
Hathcock
James
J
Mt. Sinai School of Medicine, Box #1269, Annenberg 24-92, One Gustave Levy Place, New York, New York 10029, USA. James.Hathcock@mssm.edu
Rusinova
Elena
E
Vaananen
Heikki
H
Nemerson
Yale
Y
D001550:Benzamidines / Q000737:chemistry / Q000378:metabolism; D015536:Down-Regulation / Q000502:physiology; D015942:Factor VIIa / Q000737:chemistry / Q000378:metabolism; D015951:Factor Xa / Q000737:chemistry* / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D008863:Microspheres; D010713:Phosphatidylcholines / Q000737:chemistry / Q000378:metabolism; D010718:Phosphatidylserines / Q000737:chemistry / Q000378:metabolism; D010743:Phospholipids / Q000737:chemistry* / Q000378:metabolism*; D011485:Protein Binding; D013379:Substrate Specificity; D013925:Thromboplastin / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D013997:Time Factors; D014360:Trypsin Inhibitor, Kunitz Soybean / Q000737:chemistry / Q000378:metabolism; D015854:Up-Regulation / Q000502:physiology
D001550:Benzamidines; D010713:Phosphatidylcholines; D010718:Phosphatidylserines; D010743:Phospholipids; C042511:1,2-dioleoylphosphatidylserine; D013925:Thromboplastin; D014360:Trypsin Inhibitor, Kunitz Soybean; D015942:Factor VIIa; D015951:Factor Xa; C017251:1,2-oleoylphosphatidylcholine; C032157:benzamidine